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What is the dose-limiting for altered radiotherapy for head
and neck cancers – facts and doubts
Bogus∏aw Maciejewski1, Klaus R.Trott2, Leszek Miszczyk1,
Rafa∏ Tarnawski1, Tomasz Rutkowski1
Altered fractionation radiotherapy for head and neck produces locoregional benefit at the expence of an increased incidence
and greater severity of acute reactions. This paper presents analysis of 21 data sets (2859 cases) including our own data of esca-
lated and accelerated irradiation and aims to assess to what extent H & N mucosa is limiting to dose intensification by alte-
red regimes.
The rate and speed of dose accumulation is the most important determinant for early reactions. The analysis shows that the-
re is no single predictor for severity of acute mucosal reactions, and among many fractionation parameters maximal relative
Accumulated Normalized Dose (rANDmax) for week in which acute reaction reaches the peak of severity gives the best fit to
all data, especially if α/β ratio is lower than 10 Gy. It may suggest that H & N mucosa is more sensitive to change in dose per
fraction as it is generally accepted.
Although mucosal reactions are more severe for altered fractionation regimes and troublesome for patients usually they are not
beyond the limit of tolerance. After all, they are transient. It seems that the real dose-limiting factor is consequential late effects
(CLE) which occur relatively early during follow-up and they may progress into permanent severe damage which significan-
tly decreases the comfort and quality of life of the patients. For hybrids of accelerated – hyperfractionated regimes risk of CLE
is low (<3.5%), however it increases to 15-20% for purely accelerated schedules. In order to avoid the risk of CLE, acute re-
actions should be regularly monitored during the treatment by precise and frequent scoring and recording of morphological
changes and its severity.
Jaki czynnik ogranicza dawk´ w niekonwencjonalnej radioterapii raków g∏owy i szyi – fakty i wàtpliwoÊci
Niekonwencjonalnie frakcjonowana radioterapia u chorych na raka regionu g∏owy i szyi zwi´ksza miejscowy zysk terapeutycz-
ny kosztem zwi´kszenia cz´stoÊci i nasilenia ostrych odczynów popromiennych. Aktualne opracowanie prezentuje analiz´ wy-
ników 21 badaƒ klinicznych (2859 przypadków) z uwzgl´dnieniem badaƒ w∏asnych nad przyspieszonym frakcjonowaniem
i eskalacjà dawki ca∏kowitej. Celem analizy jest ocena, w jakim stopniu ostry odczyn b∏ony Êluzowej w obszarze g∏owy i szyi jest
czynnikiem ograniczajàcym intensyfikacj´ dawki w zmiennych systemach jej frakcjonowania.
WielkoÊç i szybkoÊç akumulacji dawki promieniowania jest najistotniejszym czynnikiem determinujàcym ostry odczyn popro-
mienny. Wyniki badaƒ wskazujà na brak jednego i znamiennego czynnika predykcyjnego dla nasilenia ostrego odczynu. Spo-
Êród licznych fizycznych parametrów frakcjonowanej radioterapii, najwy˝sza wartoÊç wskaênika wzgl´dnej Znormalizowanej
Dawki Akumulowanej (rANDmax) w tygodniu, w którym ostry odczyn osiàga najwi´ksze nasilenie, najsilniej koreluje z ana-
lizowanymi danymi klinicznymi, szczególnie gdy wskaênik normalizacji α/β ma wartoÊç mniejszà ni˝ 10 Gy. To sugeruje, ˝e
b∏ona Êluzowa w obszarze g∏owy i szyi mo˝e byç bardziej wra˝liwa na zmiennoÊç dawki frakcyjnej ni˝ dotychczas sàdzono.
Pomimo, ˝e ostre odczyny popromienne w trakcie niekonwencjonalnej radioterapii sà bardziej nasilone i gorzej znoszone przez
chorych, to nie podwy˝szajà granicy tolerancji. Ponadto sà one przejÊciowe. Wyniki przeprowadzonych analiz sugerujà, ˝e rze-
czywistym czynnikiem ograniczajàcym frakcjonowanie dawki sà „nast´powe odczyny póêne” (CLE), które ujawniajà si´ sto-
sunkowo wczeÊnie po zakoƒczeniu leczenia i mogà ulec ewolucji w trwa∏e póêne uszkodzenia popromienne, obni˝ajàce jakoÊç
i komfort prze˝ycia. Dla kombinacji przyspieszonego hierfrakcjonowanego napromieniania ryzyko CLE jest niskie (3,5%), ale
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Introduction
Conventionally fractionated radiotherapy (RT) was con-
sidered as the major factor to decrease therapeutic gain.
Combination of radiotherapy with surgery and/or che-
motherapy may further increase the risk of late radiation
morbidity. As altered fractionation schedules are more
and more often explored in clinical studies, the applica-
tion of more than one fraction per day of less than 2 Gy
(hyperfractionation) produces increased sparing effects
with regard to late normal tissue damage at the expence
of an increased incidence and greater severity of acute
mucosal reactions.
It has been claimed that acute morbidity becomes
the main dose-limiting factor for altered fractionated
schedules, yet this appears to be based on belief rather
than on evidence-based conclusions.
A c u t e  m u c o s a l  r a d i a t i o n  e f f e c t s
Acute mucositis is the result of hypoplasia of the squ-
amous epithelium due to sterilization of mucosal stem
cells and inhibition of proliferation of transit cells. Fractio-
nated irradiation leads to a gradual decrease in epithelial
cell number, and when cell production can not keep up
with cell killing partial or complete denudation develops
presenting as spotted or confluent mucositis.
In conventional RT given in 1.8–2.0 Gy fractions, 5-
-times per week, confluent mucositis (CM) usually oc-
curs within about 9 days after the dose of 20 Gy is accu-
mulated [1]. The intensity of acute reactions reflects the
balance between cell kill effect and the rate of repopula-
tion of surviving stem cells. Once a peak of the CM is
reached, further increase in dose and cell killing will not
produce any further increase of the intensity of the acute
reaction, but prolongs the duration of the CM and delays
its healing.
The mucosa in the head and neck region rapidly
sheds sublethal damage and it needs very little time for re-
covery. Ang et al. [2] has found that sublethal damage in
lip mucosa is fully recovered within 3–4 hours and repair
is faster than in late responding tissues [3]. Sublethal da-
mage repair in acutely responding tissues is less important
than repopulation which effectively balances the cell kill
effect [1, 3–26]. Split – course schedules show rapid
healing of the CM during 2–3 week break and mucosal re-
actions are generally milder in the second than in the
first course of treatment. This can be ascribed to accelera-
ted repopulation during and beyond the split. Withers et
al. [6] and Van der Schueren et al. [1] suggest there is no
repopulation by clonogenic mucosal epithelial cells until
day 12–14 of conventional irradiation, but thereafter be-
tween the third and seventh week mucosal isoeffect dose
increases by about 1.0 Gy/day or even by 2.5 Gy/day du-
ring treatment breaks.
There is now a substantial number of studies using al-
tered fractionation schedules (accelerated, hyperfractiona-
ted or its hybrids), and nearly all authors have reported an
increased incidence and severity of acute mucosal reaction.
It appears that the criteria of acute morbidity are not pre-
cise enough to determine the tolerability of any particular
treatment schedule, and the majority of authors concentra-
te on grading differences of severity of usually tolerable
normal tissue reactions to distinguish clinically tolerable
from intolerable acute mucositis. Extensive clinical expe-
rience with different fractionation schedules permits the
investigation of whether or not acute mucositis is truly
dose-limiting for altered fractionated radiotherapy.
Material and methods
The results of our own 2 studies [7, 8] and those of altered frac-
tionation schedules which permit a reasonably accurate quanti-
tative assessment of acute mucosal reactions taken from the lite-
rature were selected for the analysis comprising 21 data sets of
2859 cases of head and neck cancer. They were divided into 4
subgroups depending on fractionation schedule: accelerated
(AF) – 5 data sets, hyperfractionation (HT) – 4 data sets; hybrid
accelerated-hyperfractionation (AHF) – 12 data sets, and co-
nventional fractionation (CF) includes cases of control arm in
the randomized trails from 10 out 21 data sets. Since it is rare,
even in randomized trials, for all patients to receive exactly the
same dose fractionation regimen, some liberty was taken in assi-
gning mean doses and mean overall treatment times.
D o s e  n o r m a l i z a t i o n
Because various schedules of dose intensity and fractionation are
used in the analyzed sets of data absolute or mean values of to-
tal dose, dose per fraction and overall treatment time vere used
to normalized total doses (TD) and doses accumulated per we-
ek (AD) to equivalent values (NTD, AND) if given in conventio-
nal 2.0 Gy fractions using equation [3]:
NTD(AND) = TDi (ADi) [(α/β + di)/(α/β + 2.0] – γ(OTT-14)
where TDi (ADi), di are a given total dose (accumulated dose
per week) and γ dose per fraction, OTT is overall treatment
time, and γ is a dose balancing mucosal repopulation per
day. The α/β ratio of 15.0 Gy was accepted for the calculation.
Time correction factor was calculated based on the assump-
tion the onset of mucosal repopulation on day 14 with the ave-
rage rate (γ) of 1.0 Gy/day in week 3 and 4, and 1.8 Gy/day
thereafter [6].
gwa∏townie wzrasta do 15–20% dla wy∏àcznie przyspieszonych systemów frakcjonowanie. W celu zmniejszenia tego ryzyka, ostry
odczyn popromienny powinien byç regularnie monitorowany w trakcie leczenia poprzez precyzyjnà i cz´stà ocen´ iloÊciowà
zmian morfologicznych i stopnia ich nasilenia.
Key words: altered radiotherapy, acute reactions, consequential late effects, dose – limiting factor
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Accumulate dose per week (AD), even if it is normalized
(AND), changes in consecutive weeks of treatment, and allows
to evaluate dose intensity only for a given specific fractionation
schedules, but is it is generally useless and even may bias com-
parison with other altered schedules. Thus, a relative Accumu-
lated Normalized Dose per week (rAND) was calculated for
a given week (i) as a ratio of the ANDi and ADC for co-
nventional schedule of 70 Gy given in 35 fraction in 42 days
(rANDi=ANDi/ADC). For conventional standard the ADC cor-
rected for repopulation and calculated for a consecutive weeks of
treatment (ADC1, ADC2, ADC3...ADC6) was 10 Gy, 20 Gy, 23
Gy... 20.8 Gy respectively.
E n d  p o i n t s
For the present analysis, only confluent mucositis (CM) (grade 4
EORTC or Dische score ≥13) was taken as severe acute reaction.
Consecutive Dische scores [9] larger than 13 always represent
the CM (with various rate of oedema, pain, bleeding and/or
ulceration), however with increasing degree of functional morbi-
dity. Incidence and severity of the CM was either clearly docu-
mented in tables or it has been determined from average graphi-
cal reaction patterns or deduced from objective and functional
scores. To minimize errors many papers have not been accounted
for the analysis because of unprecise or unknown scoring method
and/or qualitative characteristics of acute effects or it was impos-
sible to reconstruct fractionation parameters.
Consequential late effects (CLE) is defined as a reaction
morphologically-like typical late sequelae (massive fibrosis, epi-
thelial, soft tissue or bone necrosis), but developing early (<6
months) after completing the treatment, and secondarily after
very severe acute mucositis. If the CM healing occurred latency
period was short (generally a few weeks) to the onset of CLE,
but if it did not, the CM directly progressed into the CLE.
For the present analysis clearly documented CLE were in-
cluded, and also these which characteristics of acute reaction, the
nature and the onset of sequelae likely allow to suspect they
are consequential.
S t a t i s t i c a l  m e t h o d s
Data points representing the incidence of CM weighted by the
number of cases were plotted aqainst AND and rAND values,
and dose response curves were estimated by logistic regression.
The curve which gives the best fit to data points scattergram
was determinated by maximum – likelihood estimation and chi-
-square likelihood-ratio test was applied to calculate the good-
ness of the fit. To estimate dose-time curve for acute mucosal re-
action the NTD values for the CM in the range of 40-90% repor-
ted in 13 data sets were plotted against overall treatment time.
Tab. I. Incidence of severe confluent mucositis (CM, IVo EORTC) in relation to fractionation characteristics
No NTD2.0 OTT TI AND1 rANDmax(*) CM CLE Authors
Series schedule pts. (Gy) (days) (hours) (Gy)
AF – Accelerated
a. t.i.d 22 54.0 12 4 30.0 2.7(2) 100% 55% Paracchia et al. [10]
b. t.i.d. (3d/wk) 89 58.7 24 4 16.0 1.8(4) 90% - Lamb [11]
c. b.i.d. 82 66.0 25 6 20.0 2.64(4) 70% 5% Jackson [12]
d. escal.-CB (b.i.d.) 18 70.0 35 6 10.0 2.65(5) 90% 10% Kaanders [13]
e. q.d. (7d/wk.) 50 70.0 35 24 14.0 2.99(5) 82% 22% Maciejewski [7]
HF – Hyperfractionated
f. b.i.d. RTOG 83-13 447 64–73 38-42 4–8 11.4 1.42(6) 40% - Cox [14, 15]
g. b.i.d. RTOG 79-13 187 70.3 49 3–6 8.9 1.3(3) 23% - Marcial [16]
h. b.i.d. 41 68–76.6 45 4 11.4 1.3(3) 30% - Wend [17]
I b.i.d.
EORTC 22791 325 76.4 49 6 10.9 1.57(7) 67% - Horiot [18]
AHF – Accelerated hyperfractionated
k. t.i.d. 11 40.5 12 4 20.2 2.02(2) 100% - Awward [19]
l. tid CHART (7d/wk) 552 52.4 12 6 30.5 2.62(2) 73% - Dische [20]
m. t.i.d. 19 50.0 14 3 25.1 2.51(2) 100% - 11% Svoboda [5]
n. e.i.d. – S 173 67.3 26 2 33.6 3.36(1) 100% -26% N’guyen [21]
o. b.i.d. PMH 109 56.1 28 6 14.0 1.61(4) 63% - Cummings [22]
p. t.i.d. – S
EORTC 22851 214 70.3 34 4–6 23.4 1.86(4) 80% 13% Horiot [23]
r. b.i.d.-escal.-S 16 68.6 35 6 15.6 2.11(5) 100% - Maciejewski [8]
s. b.i.d. – escal. 12 73.4 35 6 13.8 2.71(5) 100% -16% Harari [24]
t. b.i.d. – S 28 67.5 40 6 17.8 2.71(5) 96% 7% Delaney [24]
u. b.i.d. – CB 43 70.8 42 6 8.89 1.51(6) 81% - Ang [25]
w. b.i.d. – S 321 65.6 42 4 15.6 1.56(2) 66% - Wang [26]
y. b.i.d. – CB 100 69.6 45 6 13.5 1.46(3) 60% - Johnson [27]
Conventional
(b,d,e,f,g,h,i,l,o,p) 66–72 44–49 24 8.89–10.0 1.0(1-8) 30%
(10–55%)
[NTD2.0 – Normalized Total Dose if given in 2.0 Gy fractions; AND1 – Accumulated Normalized Dose in week 1, rANDmax(*) – relative AND with
maximum value in week (*); CM – confluent mucositis;
CLE – consequential late effect; fractionation: q.d. – once-a-day; b.i.d. – twice-a-day; t.i.d. – trice-a-day; e.i.d. – eight times a day;S – split; CB – con-
comitant boost]
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Results
A c u t e  m u c o s i t i s  –  i n c i d e n c e  a n d  s e v e r i t y
Incidence of the CM in relation to various altered fractio-
nation schedules is presented in Table I. At the first glan-
ce, this table shows an increased incidence of the CM in
altered schedules compared with conventional treatment.
For the conventional 2.0 Gy fractionation regimen, a me-
an value of the CM incidence of 30% (±12.5%) was cal-
culated (Tab.II). For HF schedules the rate of CM was
about 2 times higher, and 2.5-3 times higher for hybrid
AHF and purely AF respectively (Fig. 3). The CM rates
for the last two schedules reflect an increasing risk of the
CLE.
A c c u m u l a t e d  D o s e  p e r  w e e k  ( n o r m a l i z e d
a n d  r e l a t i v e )
The assessment of the dose-effect relationship for acute
normal tissue reactions is complicated by the fact that
the acute reaction which has been influenced by a certain
radiation dose will only appear several days or even weeks
later, at which time a much higher dose has already been
accumulated. Previous analysis [24] of acute mucosal re-
actions in a large group of head and neck cancer cases tre-
ated with conventional and altered radiotherapy showed
that CM occurred more severe after higher doses per
fraction. They were, consequently, more frequent with
a higher rate of dose accumulation. This observation sug-
gests that the accumulated dose per week could be used
as a parameter to characterize the association between
dose intensity and CM incidence. Since during the first
week of RT the discrepancy between cell production and
cell killing is the greatest the choice of the AND1 in the
first week seems to be logical. Figure 1 A plots scatter-
gram of the CM rates from Table I against the AND1,
and it shows no correlation between the AND1 values
and the CM and CLE. High rates of both events equally
correspond with the AND1 of 10 Gy and 30 Gy as well. It
clearly shows that in altered fractionation schedules the
AND1 (or absolute AD1) is not a good predictor for the
Tab. II. Average relative Accumulated Normalized Dose per week (rAND) in relation to the mean incidence
of confluent mucositis (CM) and the risk of CLE for four different fractionation regimes
Fractionation rANDmax CM incidence CLE Tolerance
% ±(SD) risk
mainly conventional 1.26 30% 0% tolerable
(CF – HF) (1.0-1.51) (±12.5%)
mainly hyperfractionation 1.69 62% 0% troublesome but
(HF – HAF) (1.45-1.93) (9%) tolerable
hybrid accelerated-hyperfractionation 2.2 82% ≤3.5% severe (delayed healing)
(AHF) (1.94-2.46) (±13%) but still acceptable (small risk of CLE)
purely accelerated 2.75 90% ≈14% always severe and prolonged with
(AF) (2:4-3.0) (±8%) (8-20%) delayed healing.
p<0.001 dose-limiting (high risk of CLE)
Fig. 1. Scattergrams of confluent mucositis (CM) depending on
(A) Accumulated Normalized Dose in the firs week of treatment (AND1);  (B) relative ANDmax(i) which reaches maximum value in week (i).
[Characters correspond with data sets listed in Table I; circle – AF schedule; square -HF schedule; square within the circle – AHF schedule; small
black circle -conventional schedule; black area within the symbol corresponds with the risk of CLE]
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risk of CM and CLE, because the AD may not be con-
stant during the consecutive weeks of treatment.
It can be clearly observed if the intensity of dose ac-
cumulation is evaluated week by week during the treat-
ment (Fig. 2 A and B). If the dose accumulation is accoun-
ted for the effect of mucosal repopulation for conventio-
nal RT the AND5 and AND6 values are lower than that
for the first two weeks of RT. It convincingly supports the
Fletcher [28] observation of mucosal healing during the
last week of treatment in 75% of cases treated with co-
nventional RT and dose per fraction equal or lover than
2.0 Gy. In contrast, for altered fractionation the dose is
continuously accumulated in the rate higher than the ef-
fect of mucosal repopulation and the AND for the last
two-three weeks of treatment is higher than at the begin-
ning, which the AND1 value might be totally misleading
for because it is similar to that for CF or even smaller if
concomitant boost schedule is used (Fig. 2A). For aggres-
sive accelerated-hyperfractionated schedules (Fig. 3B) la-
sted longer than two weeks, even one-two week break
does not really change intensity of dose accumulation.
For this reason the AND values for week 1, 2, 3, etc.
and ANDmax (i) for the week (i) in which it has reached the
highest values were accounted for to the present analysis.
Figure 1 B plots a scattergram of the CM rates from Ta-
ble I against rANDmax, and the respective regression curve
was estimated. The correlation analysis showed that
among the AND parameters the rANDmax gives the best
fit to the analyzed data (Tab.III). This suggest that for
altered fractionation schedules there is no single and con-
stant week in which the respective AND value gives the
best characteristics of the risk of CM for but it differs
depending on the intensity of dose accumulation, and
the highest rAND value (rANDmax) seems to be the best
practical choice.
Tab. III. Goodness of the fit to the CM rate depending on
the AND parameter
Parameter Chi-square value
AND1* 601
AND2 value:
→ 694
= 10 Gy 719
= 4.0 Gy 739
= 2.0 Gy 746
rANDmax (**) 801
* chi-square values for AND3, AND4, AND5 were lower than for AND1,
and then they are not listed in the table
** week in which rAND reached the highest value
The majority of data points close to the regression
curve (Fig. 1 B) represent highly intensive treatments.
For rANDmax higher than 1.7 the CM rate has always be-
en above 60%. In all split-course AHF schedules, except
EORTC 22851, the incidence of CM is related to the do-
se intensity troughout the first course before the break.
Acute mucosal reactions were never more severe in the
second course than in the first part of treatment, and
they were generally well tolerated by the patients.
There were also evident fractionation traps, espe-
cially N’guyen study [21]. The authors have used only
0.9 Gy per fraction trying to keep treatment safety. Ho-
wever, by using 8 fractions per day with only 2 hours in-
terfraction intervals the rANDmax was 3.36 and even 2-
-week break between two one-week courses of such in-
Fig. 2. Normalized Dose accumulated during treatment time (A) for 3 AHF schedules compared to conventional standard; (B) for 4 AF schedules
Fig. 3. The average incidence of CM and the risk of CLE for different
altered fractionation schedules depending on rANDmax.
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tensive irradiation (Fig. 2A) did not counterbalance de-
ep and disastrous mucosal denudation which resulted in
dramatic treatment outcomes of 100% of severe CM and
26% of CLE.
Van der Schueren et al. [1] study on 4 different alte-
red fractionation schedules showed that when the
AND2(max) decreased from 46.8 Gy (sch.I) to 29.3 Gy
(sch.II) the incidence of CM decreased from 100% to
66%, and reactions were less severe and healed faster
than that during conventional RT with AND2 of 20.0 Gy.
They always subsided before the second course of irradia-
tion was started. When the AND of 16.0 Gy (in 2 days)
was followed by the 12 days breaks (sch.IV), the majority
of patients did not reach confluent mucositis although
this AND2 was repeated three more times.
The importance of dose intensity and of the posi-
tion of a concomitant boost (CB) during the treatment co-
urse has been documented by Ang and Peters [25]. When
CB is delivered during the last 2-2.5 weeks of treatment
the AND(1,2) is very misleading because it suggests that
the schedule is even less intensive than conventional RT,
whereas the rANDmax has reached the highest value of
1.51 in the last week of treatment, and it resulted in 81%
of CM. The same situation was noted for 3 studies
using dose escalation [8, 13, 24], where the rANDmax(5) in
week 5 in the range of 2.11–2.71 has corresponded with
almost 100% incidence of the CM and 10-16% rate of
consequential late effects in the two out of these studies.
In all these studies no significant increase in the severity
of acute mucosal reactions during the first four weeks of
treatment was observed. It was postponed to the end of
therapy, since the dose was not intensified until the fourth
week. Thus, for the CB and escalated altered schedules
with the high dose intensity only in the last part of treat-
ment the AND1, AND2 or AND3 seem to be a week pre-
dictor for the risk of CM.
Table II and Figure 3 shows that rANDmax significan-
tly (p<0.001) correlates with the incidence of the CM
and, in fact, only hybrids of intensive accelerated hyper-
fractionation (AHP) and mainly purely accelerated (AF)
schedules strongly correlate with the risk of consequential
late effects.
A l p h a / b e t a  r a t i o
An alpha/beta ratio reflects how sensitive are irradiated
tissues (tumours) to the change in dose per fraction.
With the data available, it is impossible to estimate direc-
tly an α/β value for acute confluent mucositis, since the-
re is no way to determine what part of the total dose
causes the peak of acute reaction. However, it was found
that among AND values normalized for different α/β
ratios that for α/β of 2.0 Gy gives the best fit to the data
points (Tab.III). This finding is indirectly supported by
our observations in the CAIR trial [7]. When the fraction
size was reduced by 10% (from 2.0 Gy to 1.8 Gy), the in-
cidence of CLE decreased from 22% to zero and the ra-
te of CM decreased from 83% to 62%. It may suggest
that oral mucosa is more sensitive to even small changes
in fraction size than it was generally assumed, and conse-
quently, it may suggest α/β value lower than 10 Gy. Ho-
wever, the influence of prolonged overall treatment time
should not be ignored.
D o s e - t i m e  r e l a t i o n s h i p
Since the accuracy of the total dose determined for a spe-
cific end-point in a given overall treatment time is un-
certain, it is very difficult to construct dose-time curves for
acute mucositis. A theoretical dose-time curves (Fig. 4,
dotted line) was drawn based on the assumption proposed
by Withers et al. [6] that 34.0 Gy in 2.0 Gy fractions given
in about 12 days produces an acute mucositis of almost
the same severity as 70.0 Gy in 35 fractions in 7 weeks and
50.0 Gy in 26 fractions in 4 weeks. This theoretical curve
is compared with the curve estimated for the analyzed
data sets (Fig. 4, solid line). The slope of this curve is
steeper than that proposed by Withers, and suggest that
repopulation of mucosal epithelial cells is able to compen-
sate on average the effect of about 1.5 Gy/day after 12–14
days of fractionated irradiation, instead of 1.0 Gy/day es-
timated by Withers.
Although many variables which are independent of
dose fractionation (i.e. individual radiosensitivity, size
and location of treatment volume) could bias this esti-
mation, the dose-time curve for the acute effect on Figu-
re 4 provides a reasonable approximation of the effect
of mucosal repopulation. Practically, it may help to calcu-
late an “effective total dose” producing the specific mor-
phological damage of mucosa which, for example, for to-
tal physical dose of 70.0 Gy given in 40 days would be
44.0 Gy (assuming repopulation rate of 1.0 Gy/day) or
only 31.0 Gy (for a repopulation rate of 1.5 Gy/day). The-
Fig. 4. Iso-effective dose-time curve for confluent mucositis (CM).
Black circles and dotted line represent theoretical curve proposed by
Withers et al. [28]
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se values are lower than the 54.0 Gy given in 12 days.
Therefore, one may expect less severe acute mucosal re-
action for conventional irradiation than for 54 Gy in 12
days, as it was in the case of CHART.
C o n s e q u e n t i a l  l a t e  e f f e c t s
According to Peters et al. [5], severe mucosal denuda-
tion with no sufficient reserve of epithelial cells to heal
and insufficient migration of the surviving cell from mar-
gins of the field into the irradiated area may cause gradu-
al progression of acute reaction into consequential late ef-
fect (CLE) occurring relatively early after the end of tre-
atment.
Table IV and Figure 5 show an increasing rate of
the CLE with higher dose intensity and shorter interfrac-
tion interval. The most dramatic series of CLE reported
by N’guyen [21] and Peracchia [10] may be related to
very short interfraction intervals and thus, to accumula-
tion of incomplete repair of sublethal damage. For the
majority of hybrid AHF schedules the CLE has been re-
ported incidentally, or indirectly described as it is in the
case of the EORTC 22851 trial [23].
Kaanders et al. [24] suggest that in addition to dose
intensity factors such as field size, anatomical site and
the performance status of the patients may also play
an important role in the development of CLE. Our re-
sults on the CAIR trial support this suggestions
showing that combination of high maximal score of
the severity of acute reaction and its long duration with
delayed healing were significantly associated with the
CLE, rather than just one of them (Tab.V). The CLE al-
ways developed within a small field which had been irra-
diated 7 days a week, and never within a larger one rece-
iving 5 day a week treatment. It is important than a 10%
decrease in fraction size (from 2.0 Gy to 1.8 Gy) witho-
ut any other changes in fractionation parameters redu-
ced the CLE risk from 22% to zero, and no more CLE
occurred.
Tab. V. Risk factors for consequential late effects
(according to Maciejewski et al. [7])
Factors CLE (-) CLE (+) Significance
Maximum
Dische score 15 18 0.04
Duration (weeks)
of score >15 1.8 3 0.06
Average score
during the period
3–11 wks 9.5 13 0.06
Large field 118 132
size (cm2) (89-118) (117-144) 0.01
Hb loss (q/dl) 0.7 1.75
during RT (0.7 – 2.2) (1.2 – 2.8) 0.02
Weight loss (kg) ≤3 ≥6
during RT 0.03
(factors such PFS, T-stage, total dose, overall treatment time
did not reach the level of significance)
Tab. IV. Consequential late mucosal reactions (CLE)
AUTHOR dose per fraction interfraction interval (hours) rANDmax CLE
N’guyen et al. (n) 0.9 Gy (8 fr/d) 2 3.36 (1) 26%
2.05 (2) (80%?)
Paracchia et al. (a) 2.0 Gy (t.i.d.) 4 2.7 (2) 55%
Maciejewski (e) 2.0 Gy (7d/wk, q.d) 24 2.99 (5) 22%
Harari (s) 2.0 Gy (b.i.d.-escal) 6 2.71 (5) 16%
Horiot (r) 1.6 Gy (t.i.d., split) 4 1.86 (4) 13%
Svobada (m) 1.7 – 2.3 Gy (t.i.d.) 3 2.51 (2) 11%
Kaanders (d) 2.0 Gy (b.i.d.-escal) 6 2.65 (5) 10%
Delaney (t) 1.8 Gy (b.i.d.) 6 2.71 (5) 7%
Jackson (c) 2.0 Gy (b.i.d.) 6 2.64 (4) 5%
Maciejewski (e) 1.8 Gy (7d/wk, q.d.) 24 2.65 (5) 0%
AHF-CF (b,f-l,o,r, u-y) 1.6 – 2.0 Gy (b.d., q.d.) > 6 < 2.0 (3-5) 0%
Fig. 5. Risk of consequential late effect (CLE) depending on the
rANDmax values
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Discussion
In radiotherapy, locoregional benefit should be balanced
against any acute and late normal tissue damage. Late
effect seriously threaten the quality and length of life,
whereas acute reactions might require a break during the
treatment, and thus may threaten the chance of tumour
control. The latter point becomes crucial when the in-
tensive altered fractionation schedules are used.
I n c i d e n c e  a n d / o r  v e r s u s  s e v e r i t y
The present results show a significant increase the CM in-
cidence by 2-3 fold for purely accelerated schedules, but
the difference between AF and AHF., and between CF
and mainly HF was less pronounced and not significant
(Tab. II). Does this mean that a high CM incidence is
dose-limiting? The incidence does not closely correlate
with the severity of CM. Although the rate of severe dys-
phagia requiring tube feeding is about 2 times higher in
AHF and AF than in CF and HF regimes, untolerable
CM generally occurred in short intensive AF and in some
escalated regimes [10–13, 24]. In contrast, split-cour-
se AHF treatments [8, 26], except EORTC 22851 [23],
were generally well tolerated. Then, more frequent CM
does not automatically mean more severe event. Even
100% incidence of CM did not necessarily required a bre-
ak during RT and may be quite well tolerated by the pa-
tient.
The CM incidence depends on the rate of dose ac-
cumulation, at least during the first two weeks of treat-
ment, whereas the severity of CM depends less on dose-
-fractionation, but other factors such as volume, anato-
mical site, patient performance status, infections and
some diseases producing mucosa degeneration and/or
atrophy prior to cancer development may play an impor-
tant role. The volume effect is well recognized altho-
ugh it is not accurately measured. Although others fac-
tors are often ignored and not accounted for the analy-
sis, the CM rates were more accurately quantified than
their severity.
The present comparison might be and probably is
hampered by many other uncertainties. Data collected
for the present analysis, although often cited in the litera-
ture, came over two decades from a variety of centres,
and thus, are likely biased by many between authors diffe-
rences, particularly in definition of the end-points. The
term “confluent mucositis” was used in some papers [27]
as a grade III, in anothers as a grade IV [1], or even gra-
de V [11]. In Marcial and Wendt studies [16, 17], the
CM rates seem to be underestimated because they are
mainly refered to the patients who required nasogastric
tube feeding. Only 5 of 21data sets present individual or
average severity-time patterns which allow accurate quan-
titation.
Further comparison shows that for almost identical
fractionation patterns (Tab. I-sets: l vs. a, and u vs. y) qu-
ite different CM rates were recorded. It might be expla-
ined by the difference in interfraction intervals. On the
other hand, difference in the CM rate in three escalated
regimes (Tab. I-sets: d, r, s) could be the results of diffe-
rent dose intensity. Despite many uncertainties in the
majority of HF and of may AHF regimes the rate and
severity of the CM did not alter the feasibility of fractio-
nation protocols, and unexpected breaks during the treat-
ment were rare. Generally, in the HF sets about 16–20%
patients required tube feeding. The CM in the AHF and
AF sets was significantly more frequent and severe than in
the former sets, expecially for concomitant boost, continu-
ous regimes without split and with short overall treat-
ment time. In these series severe dysphagia generally oc-
cured in 25-52% of patients and 30–35% of them required
tube feeding. Complete CM healing was delayed up to
8–10 months after the end of RT or even longer when
pure AF regimes were used.
Van der Schueren et al. [1] and Wang [26] have no-
ted that in altered split-course regimes weight loss was not
important. In contrast, in our CAIR trial strong correla-
tion between weight loss and severity of the CM was obse-
rved [7]. Weight loss of more than 5 kg occured in 54% of
patients with very severe CM lasting longer than 3 weeks,
and some of these patients developed consequential late
effects.
D o  w e  h a v e  p r e d i c t o r s  o f  t h e  r i s k  a n d  s e -
v e r i t y  o f  C M ?
In altered radiotherapy currently tested various parame-
ters are strongly and usually simultaneously changed.
Thus, it is difficult to estimate the relationship between
the acute response of normal tissue and the dose intensi-
ty. Moreover, even if accumulated dose per week is nor-
malized to 2.0 Gy fraction regime it usually is not constant
during treatment. The AND1 or AND2 (the first two we-
eks of RT) may strongly correlate with the risk of CM
only if intensive dose-fractionation is concentrated in the
initial part of treatment before split (CHART, CB,
EORTC 228451) or when the OTT is very short (Parac-
chia, Awward, Svoboda). This correlation becomes weak
and misleading if the dose intensity increases continu-
ously (CAIR) or at the and of treatment (Harari, Kaan-
ders).
The present analysis shows that best fit to the CM ra-
tes gives the relative AND(max) in the week in which it
reaches the highest value, and probably for α/β value lo-
wer than 10.0 Gy. Heterogeneity of data sets and fractio-
nation parameters may bias the present results, and thus,
the low alpha/beta value should only be interpreted as
a suggestion, not as a definitive value. However, support
for this suggestion comes from the CAIR trial where
small reduction in fraction size from 2.0 Gy to 1.8 Gy de-
creased the 22% risk of CLE to zero. Although the pre-
sent results suggest that the rANDmax might be practi-
cally a useful parameters it seems there is no single pre-
dictor for the risk of severe CM. Combination of a few
items (rAND, time-speed to reach a peak of severity and
its duration, weight and Hb loss, treatment volume) might
be predictable rather than just one of them.
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W h a t  s h o u l d  b e  c o n s i d e r e d  a s  a d o s e - l i m i -
t i n g ?
The most important point is „what is the battle about”,
that means what we understand as a tolerance-limit for
acute responding tissues. Is it prolonged severe confluent
mucositis, delayed healing or severe functional effects as
dysphagia requiring tube feeding? There is convincing
evidence that this is not the case. Although confluent
mucositis is a frequent complication during radiotherapy
and it is associated with very unpleasant symptoms such as
pain or dysphagia, it usually is manageable and certainly
not beyond the limit of patient tolerance as the price for
cure. Above all, it is transient. The term tolerance defines
the response of the patient to acute or late normal tissue
reactions. Thus, the increased severity of the injury and
the reduced tolerance reflects the response of the pa-
tient, and not necessarily the response of the tissue [24].
Therefore, the clinically relevant criterium of acute, sub-
acute tolerance after radiotherapy of head and neck can-
cers should not be determined by confluent mucositis
(whatever its severity) but by consequential late effects
which have to be avoided, if possible. The CLE is clearly
beyond the limit of tolerance because it is difficult to ma-
nage therapeutically and may lead to permanent morbidi-
ty. Present results demonstrate that among various altered
fractionation schedules and the majority of AF regimes
and only some of the AHF hybrid might be at the high
risk of CLE and the rAND higher than 2.6 could be con-
sidered as dose-limiting predictor for unacceptable risk of
the CLE (Tab. II, Fig. 1B).
High the rAND value may reflect fast increase in
the severity of acute reaction toward the early peak of
confluent mucositis with the progress in dysphagia, pain
on swallowing and weight loss. In such cases the risk of
CLE might be decreased by early administration of syste-
mic corticosteroids, antibiotics, parenteral nutrition or
acute reaction modifiers. Above all, in order to recognize
such danger situation for the individual patient and to
establish the limitation of altered fractionation regime
precise quantitative and regular scoring of acute reac-
tions is needed. Our experience with the Dische scoring
system [7–9] shows its practical adavantages because it
places emphasis on both functional disorders and mor-
phological changes. However, the use of an appropriate
scoring system does not by itself solve the problem of as-
sessment of the limits of tolerance, unless acute reactions
are regularly scored during the treatment and thereafter,
until complete healing is achieved.
H o w  t h e  g a m e  s h o u l d  b e  p l a y e d
The present analysis shows that the mucosal epithelium is
able to compensate the effect of 1.5 Gy/day between the
second and seventh week of treatment and it is higher
value than 1.0 Gy/day postulated by Withers et al. [6]. It li-
kely seems that during last 2–3 weeks of 7-week schedule
it could even increase to 1.8 Gy/day and may be to 2.5
Gy/day during the weekends. Thus, mucosal repopula-
tion is more effective and begins earlier than that by survi-
ving tumour clonogens. If one wishes to use intensive do-
se fractionation schedule, the longer dose is delivered
difference between tumour and mucosa repopulation be-
comes smaller and smaller.
Kaanders et al. point out that in most patients the
mucosa can not compensate dose greater than 10 Gy per
week [24]. However, it does not seem true. In the
CHART the AND1 of 30.5 Gy or 23.4 Gy in the EORTC
22851 trial did not result in extremely high incidence of
CM but the former schedules lasted only 12 days, and in
the second one after the first two weeks of irradiation
12-14 day break was introduced. In contrast, the AND1 of
14 Gy in CAIR trial was too much [7]. It may suggest
that the most important is „how the game is played”, it
means, how fast and in what rate the dose is accumulated
during the treatment.
Analyzing advantages and disadvantages of the
EORTC 22851 trial [23] and the CAIR [7]. Kaanders et
al. [24] concluded than none of many clinical and physi-
cal parameters could satisfactorily explain the greater
acute toxicity of CAIR. However, despite the fact that
the EORTC-AHF was the split-course schedule, the most
important difference is that it was “weekend-free” treat-
ment, in contrast to CAIR which was “weekend continu-
ed”. The regular 24-hours intervals between 2.0 Gy frac-
tions continued over 5 weeks were probably not long
enough for effective compensation of progressive denu-
dation of epithelium leading to persisted severe mucosal
reaction finally progressed into the CLE in 22% of pa-
tients. Thus, regular weekend breaks and split periods li-
kely allow mucosa repopulation to compensate radia-
tion injury. Mucosa repopulation during short or longer
breaks seems to be more effective than during the irra-
diated weekdays. In contrast, 6–7 days per week sche-
dule results in regular continuous dose accumulation
(Fig. 2B), and in week 4 of treatment the AND higher
than 40 Gy strongly correlates with a high risk of dose-li-
miting consequential late effect. It corresponds with abo-
ut 60 Gy of uncorrected total dose. Thus, 60 Gy in 4–5
weeks can still be tolerated [24], and there is no reason to
shorten the OTT to 1.5–2 weeks, because the reduction
in total dose neutralizes the expected local tumour con-
trol.
It has to be kept in mind that a severity of acute ef-
fects strongly correlates with tumour control. This is not
surprising since they both are a function of dose accu-
mulation. Although, this observation may seems obvious,
the converse is of practical significance; mild acute reac-
tions during RT may be related to an increased risk of tre-
atment failure. Thus, optimal therapeutic gain might be
achieved if altered fractionation regimes produce acute
mucosal reaction at the level as high possible but still to-
lerable by the patient.
Conclusions
Although it is necessary to be aware of the limitations of
the present analyses and of some uncertainties regarding
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the precise averages, the following implications can be
formulated:
1. Assessment of frequency and severity of acute mucosal
reactions in radiotherapy, at least for head and neck re-
gion, requires regular recording of morphological and
functional effects until complete healing is achieved
using the accurate scoring system, and reaction pat-
tern should be plotted for each individual patient.
2. It seems that maximal relative accumulated normalized
dose per week (rADMmax) could be a good estimator
of the incidence of confluent mucositis, and partly of its
severity.
3. It is important to be aware of the risk of consequential
late effects which are the true dose-limiting compli-
cations of radiotherapy of head and neck cancer, not,
however, transient confluent mucositis.
4. The tendency of doctors to be kind to patients by mini-
mizing acute toxicity is likely to be unkind to them by
decreasing probability of tumour control.
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